<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">pmed</journal-id><journal-id journal-id-type="publisher-id">plme</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><journal-title>PLoS Medicine</journal-title><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18271624</article-id><article-id pub-id-type="pmc">2235897</article-id><article-id pub-id-type="doi">10.1371/journal.pmed.0050043</article-id><article-id pub-id-type="publisher-id">07-PLME-RIT-1386R2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research in Translation</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cardiovascular Disorders</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Microbiology</subject><subject>Pharmacology</subject></subj-group><subj-group subj-group-type="System Taxonomy"><subject>Infectious Diseases</subject><subject>Immunology and Allergy</subject><subject>Hematology (including Blood Transfusion)</subject></subj-group></article-categories><title-group><article-title>Salivating for Knowledge: Potential Pharmacological Agents in Tick Saliva</article-title><alt-title alt-title-type="running-head">Research in Translation</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hovius</surname><given-names>Joppe W. R</given-names></name><xref ref-type="corresp" rid="cor1">&#x0002a;</xref></contrib><contrib contrib-type="author"><name><surname>Levi</surname><given-names>Marcel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fikrig</surname><given-names>Erol</given-names></name></contrib></contrib-group><author-notes><corresp id="cor1">&#x0002a; To whom correspondence should be addressed. E-mail: <email>j.w.hovius&#x00040;amc.uva.nl</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2008</year></pub-date><pub-date pub-type="epub"><day>12</day><month>2</month><year>2008</year></pub-date><volume>5</volume><issue>2</issue><elocation-id>e43</elocation-id><copyright-statement><bold>Copyright:</bold> &#x000a9; 2008 Hovius et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract abstract-type="toc"><p>Joppe Hovius and colleagues review anticoagulant and immunosuppressive proteins present in tick saliva, and discuss how immunologically targeting such molecules could prevent transmission of tick-borne pathogens.</p></abstract><counts><page-count count="7"/></counts><custom-meta-wrap><custom-meta><meta-name>citation</meta-name><meta-value>Hovius JWR, Levi M, Fikrig E (2008) Salivating for knowledge: Potential pharmacological agents in tick saliva. PLoS Med 5(2): e43. doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.pmed.0050043">10.1371/journal.pmed.0050043</ext-link></meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><p>The incidence of tick-borne diseases has drastically increased over the past few years &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b001">1</xref>,<xref ref-type="bibr" rid="pmed-0050043-b002">2</xref>&#x0005d;, resulting in a marked increase in research on tick&#x02013;host&#x02013;pathogen interactions. As a result, the knowledge on molecules present in tick saliva and their function has significantly expanded &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b003">3</xref>,<xref ref-type="bibr" rid="pmed-0050043-b004">4</xref>&#x0005d;. Ticks are obligate hematophagous ectoparasites, and hundreds of tick species are distributed worldwide. While taking a blood meal, ticks are attached to their host for several days and introduce saliva into the host skin. Like saliva from other hematophagous animals, such as mosquitoes, flies, leeches, and nematode species, tick saliva contains a wide range of physiologically active molecules that are crucial for attachment to the host or for the transmission of pathogens &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b005">5</xref>&#x0005d;, and that interact with host processes, including coagulation and fibrinolysis, immunity and inflammation, and angiogenesis &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b003">3</xref>,<xref ref-type="bibr" rid="pmed-0050043-b006">6</xref>,<xref ref-type="bibr" rid="pmed-0050043-b007">7</xref>&#x0005d;. In this article, we discuss molecules in tick saliva that have been intensively studied in vitro or in animal models for human diseases, and that, due to their specificity, are potential future anticoagulant or immunosuppressive agents. We also discuss how immunologically targeting specific tick salivary proteins could prevent the transmission of tick-borne pathogens from the tick to the host.</p><sec id="s2"><title>Anticoagulants</title><p>The hemostatic response enables mammals to control blood loss during vascular injury. Platelets adhere to macromolecules in exposed subendothelial tissue and aggregate to form a hemostatic plug, while local activation of plasma coagulation factors leads to generation of a fibrin clot that reinforces the platelet aggregate. The coagulation cascade starts when exposed subendothelial tissue factor (TF) binds to activated factor VII (FVIIa). This complex activates factor X (forming FXa), which mediates the formation of minute amounts of thrombin that activate other coagulation proteases and additional platelets. Subsequently, by means of two amplification loops (<xref ref-type="fig" rid="pmed-0050043-g001">Figure 1</xref>), more thrombin is generated, which leads to fibrinogen-to-fibrin conversion and fibrin deposition &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b008">8</xref>&#x0005d;.</p><fig id="pmed-0050043-g001" position="float"><label>Figure 1</label><caption><title>Schematic Overview of the Coagulation Cascade</title><p>The two major amplification loops in the coagulation cascade are depicted. The first amplification loop consists of TF-FVIIa-mediated factor IX (FIX) activation, which leads to the generation of more FXa. A second amplification loop is formed by the activation of factor XI (FXIa) by thrombin, which results in more activated FIX (FIXa), and, subsequently, additional FXa generation. The right panel indicates how selected tick proteins exert their anticoagulant effect.</p><p>FIIa, activated factor II; FVa, activated factor V; FVIIIa, activated factor VIII.</p></caption><graphic xlink:href="pmed.0050043.g001"/></fig><p>Tick feeding is hampered by the hemostatic response of the host. Therefore tick saliva contains an extensive selection of molecules that counteract coagulation, enhance fibrinolysis, and inhibit platelet aggregation &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b007">7</xref>&#x0005d;. Traditional anticoagulant agents such as unfractionated heparin and vitamin K antagonists (e.g., warfarin) have a narrow therapeutic index, requiring frequent monitoring and dose adjustments &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b007">7</xref>&#x0005d;. Tick saliva presents a possible source of novel, and ideally more easily used, anticoagulant agents (<xref ref-type="fig" rid="pmed-0050043-g001">Figure 1</xref>) &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b007">7</xref>&#x0005d;.</p><boxed-text position="float"><title>Five Key Papers in the Field</title><p><bold>Hepburn et al., 2007</bold> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b040">40</xref>&#x0005d; After identification of a specific activated C5 inhibitor, OMCI, the authors showed how this protein can be used in an experimental animal model for myasthenia gravis.</p><p><bold>Paveglio et al., 2007</bold> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b050">50</xref>&#x0005d; Showed that a T cell inhibitor from tick saliva, Salp15, is able to prevent the development of pathological features in an animal model for atopic asthma.</p><p><bold>Labuda et al., 2006</bold> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b055">55</xref>&#x0005d; Showed that an anti-tick vaccine, directed against the 64TRP cement protein in tick saliva, prevented lethal infection of mice with the tick-borne encephalitis virus, indicating that anti-tick vaccines could be used to combat tick-borne pathogens.</p><p><bold>Ramamoorthi et al., 2005</bold> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b005">5</xref>&#x0005d; Showed that <named-content content-type="genus-species">B. burgdorferi</named-content>, the causative agent of Lyme disease, uses a protein in tick saliva, Salp15, to establish an infection in the mammalian host, underscoring the complex tick&#x02013;host&#x02013;pathogen interactions that are involved in the development of Lyme disease.</p><p><bold>Waxman et al., 1990</bold> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b009">9</xref>&#x0005d; Identified the first highly specific activated factor X inhibitor in tick saliva, TAP. This research has been the inspiration for numerous researchers working in the field of coagulation.</p></boxed-text><sec id="s2a"><title>Factor Xa inhibitors.</title><p>Saliva from the soft tick <named-content content-type="genus-species">Ornithodoros moubata</named-content> contains a serine protease inhibitor of FXa&#x02014;tick anticoagulant peptide (TAP). TAP is a tight-binding specific FXa inhibitor that inhibits clotting of human plasma ex vivo &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b009">9</xref>&#x0005d;. The inhibitory characteristics and the high selectivity of recombinant forms of TAP (rTAP) for FXa are due to the interaction of rTAP with the active site as well as with regions remote from the active site pocket of FXa &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b010">10</xref>&#x0005d;. rTAP has been tested in a variety of animal models for both venous and arterial thrombosis &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b011">11&#x02013;13</xref>&#x0005d;. A recent study showed that rTAP, when fused to a single-chain antibody specifically targeting activated platelets (through binding to the platelet receptor GPIIb/IIIa), had highly effective antithrombotic properties in comparison to enoxaparin in a murine carotid artery thrombosis model. In addition, in contrast to conventional anticoagulants tested, the TAP&#x02013;antibody fusion protein did not prolong bleeding time &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b014">14</xref>&#x0005d;. Future research should reveal whether this or similar approaches are equally effective and safe in humans. Other FXa inhibitors characterized in tick saliva are shown in <xref ref-type="table" rid="pmed-0050043-t001">Table 1</xref> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b015">15</xref>,<xref ref-type="bibr" rid="pmed-0050043-b016">16</xref>&#x0005d;.</p><table-wrap id="pmed-0050043-t001" content-type="8col" position="float"><label>Table 1</label><caption><p>Anticoagulants and Immunosuppressors in Tick Saliva</p></caption><graphic xlink:href="pmed.0050043.t101"/></table-wrap><table-wrap id="pmed-0050043-t102" content-type="8col" position="float"><label>Table 1</label><caption><p>Continued.</p></caption><graphic xlink:href="pmed.0050043.t102"/></table-wrap></sec><sec id="s2b"><title>Tissue factor pathway inhibitors.</title><p>In view of the central role of TF in the initiation of coagulation in both physiological and pathological states, targeting TF may be an effective antithrombotic strategy. Tick saliva contains several TF pathway inhibitors (TFPIs) (<xref ref-type="table" rid="pmed-0050043-t001">Table 1</xref>) &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b007">7</xref>,<xref ref-type="bibr" rid="pmed-0050043-b017">17</xref>&#x0005d;. Recently, Ixolaris was identified in saliva from the deer tick <named-content content-type="genus-species">Ixodes scapularis</named-content> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b017">17</xref>&#x0005d;. Ixolaris has two kunitz-like domains, a type of domain conserved in a wide family of serine protease inhibitors, and sequence homology to human TFPI &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b018">18</xref>&#x0005d;. In a rat model for venous thrombosis, administration of recombinant Ixolaris resulted in effective antithrombotic activity, without hemorrhage or bleeding &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b019">19</xref>&#x0005d;. Because of its fast and tight binding to FXa, giving rapid-acting, selective, and long-lasting effects, and the encouraging results in vivo, Ixolaris could serve as a template for potential new anticoagulant agents targeting the TF pathway.</p></sec><sec id="s2c"><title>Direct thrombin inhibitors.</title><p>In comparison with heparin (derivatives), which act via antithrombin, direct thrombin inhibitors more effectively inhibit clot-bound thrombin, which is likely to result in a stronger antithrombotic effect &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b020">20</xref>&#x0005d;. Several specific direct thrombin inhibitors have been characterized in tick saliva (<xref ref-type="table" rid="pmed-0050043-t001">Table 1</xref>) &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b007">7</xref>,<xref ref-type="bibr" rid="pmed-0050043-b021">21&#x02013;24</xref>&#x0005d;, but most have not yet been tested in vivo. Recently a new direct thrombin inhibitor, variegin &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b025">25</xref>&#x0005d;, was characterized from the tropical bont tick, <named-content content-type="genus-species">Amblyomma variegatum</named-content>, and shown to be structurally similar to, but much more potent than, hirulog, a 20-amino-acid synthetic thrombin inhibitor based on the natural leech peptide hirudin. Hirulog belongs to a class of drugs that have been approved for treatment of patients with acute coronary syndromes who are undergoing percutaneous coronary intervention &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b026">26</xref>&#x0005d;.</p></sec></sec><sec id="s3"><title>Immunosuppressors</title><p>Cellular innate immune responses, depending on invariant receptors such as the Toll-like receptors, are one of the first lines of defence against invading microbes. Another important innate defence system is the complement cascade. Activation of the complement system leads to opsonization of an invading pathogen as well as formation of the membrane attack complex that can lyse invading bacteria. The more specific adaptive immune response, which responds against pathogens that bypass the innate immune response, is triggered when activated antigen-presenting cells migrate to lymphoid tissue. In lymph nodes, antigen-presenting cells present processed antigen to T cells, which, upon activation, play a central role in cellular immune responses at the site of infection, or assist in the activation of B cells for the generation of an antigen-specific humoral response.</p><p>Ticks acquire a blood meal over a period of days, allowing the host sufficient time to generate anti-tick immune responses. The tick, in turn, has developed mechanisms to protect itself against host inflammation and immune responses &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b004">4</xref>&#x0005d;. In light of the central role of the complement cascade and T and B cells in many human diseases, we focus on specific tick salivary molecules that target these responses.</p><sec id="s3a"><title>Complement inhibitors.</title><p>The complement system is involved in the pathogenesis of many autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis, and also in ischemia-reperfusion injury as observed in acute myocardial infarction or ischemic stroke &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b027">27&#x02013;29</xref>&#x0005d;. Inhibitors of the complement cascade are therefore of potential clinical interest. Many agents inhibit complement factor 3 (C3) convertase early in the complement cascade, but this inhibition can result in immunosuppression, impairment of opsonization, or immune complex deposition. Novel complement inhibitors should therefore preferably inhibit the complement cascade downstream of complement factor 5 (C5), allowing the upstream cascade to proceed physiologically. Early randomized controlled clinical trials studying the effect of an antibody targeting C5 in acute myocardial infarction showed promising results &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b030">30</xref>,<xref ref-type="bibr" rid="pmed-0050043-b031">31</xref>&#x0005d;, although a more recent randomized controlled trial showed no beneficial effect on all-cause mortality of a C5-antibody compared to placebo &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b032">32</xref>&#x0005d;. A similar antibody was shown to be effective in the treatment of autoimmune diseases &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b033">33</xref>&#x0005d;.</p><p>Tick saliva contains many molecules that specifically inhibit complement activation (<xref ref-type="table" rid="pmed-0050043-t001">Table 1</xref>) &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b034">34&#x02013;38</xref>&#x0005d;. A promising tick complement inhibitor is the C5 activation inhibitor from the soft tick <named-content content-type="genus-species">O. moubata</named-content>, OMCI &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b034">34</xref>,<xref ref-type="bibr" rid="pmed-0050043-b039">39</xref>&#x0005d;. OMCI inhibits C5 activation by interfering with C5 convertase &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b039">39</xref>&#x0005d;, and has been shown to inhibit human complement hemolytic activity and the development of pathological features in a rodent model for autoimmune myasthenia gravis &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b040">40</xref>&#x0005d;.</p></sec><sec id="s3b"><title>B cell inhibitors.</title><p>The <named-content content-type="genus-species">I. ricinus</named-content> B cell inhibitory protein (BIP) is one of the tick salivary proteins that suppress proliferation of murine B cells (<xref ref-type="table" rid="pmed-0050043-t001">Table 1</xref>) &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b041">41</xref>,<xref ref-type="bibr" rid="pmed-0050043-b042">42</xref>&#x0005d;. Suppression of B cell responses benefits the tick by inhibiting specific anti-tick antibody responses that could lead to rejection by the host. In addition, B cells are unable to respond adequately to <named-content content-type="genus-species">Borrelia burgdorferi</named-content> antigens in the presence of BIP, suggesting that <named-content content-type="genus-species">B. burgdorferi</named-content> might also benefit from BIP-mediated B cell suppression. Specific inhibition of B cells has been shown to be effective in clinical studies of lymphoproliferative disorders and autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b043">43</xref>,<xref ref-type="bibr" rid="pmed-0050043-b044">44</xref>&#x0005d;. In order to serve as a template for novel drugs specifically targeting B cells, tick B cell inhibitors need further characterization.</p></sec><sec id="s3c"><title>T cell inhibitors.</title><p>The <named-content content-type="genus-species">I. scapularis</named-content> 15 kDa salivary protein, Salp15, is an example of a feeding-induced protein that inhibits the activation of T cells (<xref ref-type="table" rid="pmed-0050043-t001">Table 1</xref>) &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b045">45&#x02013;49</xref>&#x0005d;. Salp15 specifically binds to the CD4 molecule on CD4<sup>&#x0002b;</sup> T (helper) cells, which results in inhibition of T cell receptor&#x02013;mediated signaling, leading to reduced interleukin-2 production and impaired T cell proliferation &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b046">46</xref>&#x0005d;. In an experimental mouse model of allergic airway disease, Salp15 prevented the development of atopic asthma &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b050">50</xref>&#x0005d;, suggesting that Salp15 might be used to modulate atopic disease as well as T cell&#x02013;driven autoimmune diseases. We have shown that Salp15 also inhibits inflammatory cytokine production by human monocyte-derived dendritic cells by interacting with the C-type lectin receptor DC-SIGN &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b051">51</xref>&#x0005d;, indicating that Salp15 has the potential to modulate human adaptive immune responses. Iris, an immunosuppressive protein from <named-content content-type="genus-species">I. ricinus</named-content>, has been shown to modulate T cell responses through inhibition of interferon- and to inhibit interleukin-6 and tumor necrosis factor-a production by human macrophages &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b049">49</xref>&#x0005d;. In addition, Iris also has been shown to have anti-hemostatic effects by inhibiting several serine proteases involved in the coagulation cascade and fibrinolysis &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b052">52</xref>&#x0005d;.</p></sec></sec><sec id="s4"><title>New Strategies to Prevent Tick-Borne Diseases</title><p>Understanding the importance of specific tick salivary proteins for attachment to the host and for transmission of pathogens may permit us to develop new strategies (e.g., anti-tick vaccines) for preventing tick-borne diseases. The idea of a tick-antigen-based vaccine is supported by the observation that repeated exposure of certain animals to tick bites results in an inability of ticks to successfully take a blood meal &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b045">45</xref>&#x0005d;. These animals, as well as humans who develop hypersensitivity after repeated tick bites &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b049">49</xref>&#x0005d;, are less likely to be infected by tick-borne pathogens &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b053">53</xref>&#x0005d;. Ideally, an anti-tick vaccine would protect against infestation by a wide range of tick species and prevent transmission of multiple tick-borne pathogens. Discussing all tick antigens that have been assessed in vaccination trials is beyond the scope of this article. For an overview of the current stage of development of anti-tick vaccines, there is an excellent review available &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b054">54</xref>&#x0005d;. An interesting example of an anti-tick vaccine that also protects against the transmission of a tick-borne pathogen is a vaccine targeting the salivary cement protein, 64P, from the tick <named-content content-type="genus-species">Rhipicephalus appendiculatus</named-content> &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b055">55</xref>,<xref ref-type="bibr" rid="pmed-0050043-b056">56</xref>&#x0005d;. Tick feeding on animals immunized with truncated recombinant forms of 64P (64TRP) resulted in local inflammatory responses and protection against infestation by a wide range of tick species &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b056">56</xref>&#x0005d;. Importantly, 64TRP-vaccinated mice challenged with tick-borne encephalitis virus (the most important human vector-borne viral infection in Europe &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b057">57</xref>&#x0005d;) through tick bite were protected from lethal encephalitis &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b055">55</xref>&#x0005d;.</p><p>Proteins that enhance tick feeding may also modulate host immune responses to pathogens, thus playing a double role in transmission. For example, an <named-content content-type="genus-species">I. scapularis</named-content> tick can introduce both Salp15 and <named-content content-type="genus-species">B. burgdorferi</named-content> into the host skin. As described earlier, Salp15 may enhance tick feeding by inhibiting host immune responses to tick antigens. In addition, the <named-content content-type="genus-species">B. burgdorferi</named-content> outer surface protein C (OspC) has been shown to bind to Salp15 in tick saliva &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b005">5</xref>&#x0005d;. This binding acts as a shield that protects the spirochete against the host immune response (<xref ref-type="fig" rid="pmed-0050043-g002">Figure 2</xref>). Salp15 would therefore be a candidate to consider for immunization studies. Also, the pleiotropic protein Iris, that not only modulates T cell responses, but also specifically disrupts coagulation &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b052">52</xref>&#x0005d;, could be an interesting candidate. Recently, it was shown that vaccinating rabbits with Iris partially protected these rabbits from tick infestations &#x0005b;<xref ref-type="bibr" rid="pmed-0050043-b058">58</xref>&#x0005d;.</p><fig id="pmed-0050043-g002" position="float"><label>Figure 2</label><caption><title>Diagram Showing How an Anti-Salp15 Vaccine Could Prevent Transmission of <named-content content-type="genus-species">B. burgdorferi</named-content></title><p>During tick feeding and early mammalian infection, <named-content content-type="genus-species">B. burgdorferi</named-content> expresses OspC, which binds to Salp15 in tick saliva. This binding acts as a shield and protects the spirochete from killing by the host. In addition, Salp15 has been shown to directly inhibit dendritic cell and T cell activation, which could facilitate tick feeding. Salp15 antibodies are likely to bind to Salp15 that has previously bound to OspC on the surface of <named-content content-type="genus-species">B. burgdorferi</named-content> in the tick salivary gland and could thereby enhance clearance by host phagocytic immune cells. Obviously, the Salp15 antibodies would need to recognize a Salp15 epitope other than the epitope that is required for binding of Salp15 to OspC. Similarly, if anti-Salp15 antibodies were to bind to free Salp15, they could neutralize the immunosuppressive effects of Salp15, which could hamper tick feeding and thereby transmission of <named-content content-type="genus-species">B. burgdorferi</named-content> from the tick to the host. Lastly, if anti-Salp15 antibodies were to inhibit binding of Salp15 to <named-content content-type="genus-species">Borrelia</named-content> OspC, this would render the spirochete susceptible to pre-existing or newly generated immunoglobulins. Importantly, Salp15 was originally identified by screening of a tick salivary gland cDNA expression library with tick immune rabbit sera, suggesting that antibodies against Salp15 may participate in tick rejection.</p><p>DC, dendritic cell; MHC, major histocompatibility complex; MF, macrophage; TCR, T cell receptor.</p></caption><graphic xlink:href="pmed.0050043.g002"/></fig></sec><sec id="s5"><title>Conclusion</title><p>Tick saliva is a potential source for novel pharmacological agents that could be useful for clinical practice. Future research must confirm whether these specific and potent molecules, with promising results in animal models and in human ex vivo experiments, are effective in humans in vivo. The molecules discussed are only a selection of the many physiologically active molecules that have been identified and characterized. However, this selection illustrates the impressive resourcefulness that ticks display to modulate host processes, and demonstrates how we could use these molecules to our benefit. Undoubtedly, future research on tick&#x02013;host and tick&#x02013;host&#x02013;pathogen interactions will reveal even more potential molecules that could be used in clinical practice.</p></sec></body><back><ack><p>We thank Rick Henderik for his help with the extensive literature search for publications relevant for the discussed topics and Christian Stutzer for the generation of <xref ref-type="fig" rid="pmed-0050043-g002">Figure 2</xref>.</p></ack><glossary><def-list><title>Abbreviations</title><def-item><term>64TRP</term><def><p>truncated recombinant forms of 64P</p></def></def-item><def-item><term>BIP</term><def><p>B cell inhibitory protein</p></def></def-item><def-item><term>C3</term><def><p>complement factor 3</p></def></def-item><def-item><term>C5</term><def><p>complement factor 5</p></def></def-item><def-item><term>FVIIa</term><def><p>activated factor VII</p></def></def-item><def-item><term>FXa</term><def><p>activated factor X</p></def></def-item><def-item><term>OspC</term><def><p>outer surface protein C</p></def></def-item><def-item><term>rTAP</term><def><p>recombinant forms of TAP</p></def></def-item><def-item><term>TAP</term><def><p>tick anticoagulant peptide</p></def></def-item><def-item><term>TF</term><def><p>tissue factor</p></def></def-item><def-item><term>TFPI</term><def><p>TF pathway inhibitor</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="pmed-0050043-b001"><citation citation-type="journal"><person-group><name><surname>Steere</surname><given-names>AC</given-names></name><name><surname>Coburn</surname><given-names>J</given-names></name><name><surname>Glickstein</surname><given-names>L</given-names></name></person-group><year>2004</year><article-title>The emergence of Lyme disease</article-title><source>J Clin Invest</source><volume>113</volume><fpage>1093</fpage><lpage>1101</lpage><pub-id pub-id-type="pmid">15085185</pub-id></citation></ref><ref id="pmed-0050043-b002"><citation citation-type="journal"><person-group><name><surname>Dumler</surname><given-names>JS</given-names></name><name><surname>Choi</surname><given-names>KS</given-names></name><name><surname>Garcia-Garcia</surname><given-names>JC</given-names></name><name><surname>Barat</surname><given-names>NS</given-names></name><name><surname>Scorpio</surname><given-names>DG</given-names></name><etal/></person-group><year>2005</year><article-title>Human granulocytic anaplasmosis and <named-content content-type="genus-species">Anaplasma phagocytophilum</named-content></article-title><source>Emerg Infect Dis</source><volume>11</volume><fpage>1828</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">16485466</pub-id></citation></ref><ref id="pmed-0050043-b003"><citation citation-type="journal"><person-group><name><surname>Brossard</surname><given-names>M</given-names></name><name><surname>Wikel</surname><given-names>SK</given-names></name></person-group><year>2004</year><article-title>Tick immunobiology</article-title><source>Parasitology</source><volume>129</volume><issue>Suppl</issue><fpage>S161</fpage><lpage>S176</lpage><pub-id pub-id-type="pmid">15940820</pub-id></citation></ref><ref id="pmed-0050043-b004"><citation citation-type="journal"><person-group><name><surname>Valenzuela</surname><given-names>JG</given-names></name></person-group><year>2004</year><article-title>Exploring tick saliva: from biochemistry to &#x02018;sialomes&#x02019; and functional genomics</article-title><source>Parasitology</source><volume>129</volume><issue>Suppl</issue><fpage>S83</fpage><lpage>S94</lpage><pub-id pub-id-type="pmid">15938506</pub-id></citation></ref><ref id="pmed-0050043-b005"><citation citation-type="journal"><person-group><name><surname>Ramamoorthi</surname><given-names>N</given-names></name><name><surname>Narasimhan</surname><given-names>S</given-names></name><name><surname>Pal</surname><given-names>U</given-names></name><name><surname>Bao</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name><etal/></person-group><year>2005</year><article-title>The Lyme disease agent exploits a tick protein to infect the mammalian host</article-title><source>Nature</source><volume>436</volume><fpage>573</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">16049492</pub-id></citation></ref><ref id="pmed-0050043-b006"><citation citation-type="journal"><person-group><name><surname>Fukumoto</surname><given-names>S</given-names></name><name><surname>Sakaguchi</surname><given-names>T</given-names></name><name><surname>You</surname><given-names>M</given-names></name><name><surname>Xuan</surname><given-names>X</given-names></name><name><surname>Fujisaki</surname><given-names>K</given-names></name></person-group><year>2006</year><article-title>Tick troponin I-like molecule is a potent inhibitor for angiogenesis</article-title><source>Microvasc Res</source><volume>71</volume><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">16631826</pub-id></citation></ref><ref id="pmed-0050043-b007"><citation citation-type="journal"><person-group><name><surname>Maritz-Olivier</surname><given-names>C</given-names></name><name><surname>Stutzer</surname><given-names>C</given-names></name><name><surname>Jongejan</surname><given-names>F</given-names></name><name><surname>Neitz</surname><given-names>AW</given-names></name><name><surname>Gaspar</surname><given-names>AR</given-names></name></person-group><year>2007</year><article-title>Tick anti-hemostatics: targets for future vaccines and therapeutics</article-title><source>Trends Parasitol</source><volume>23</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">17656153</pub-id></citation></ref><ref id="pmed-0050043-b008"><citation citation-type="journal"><person-group><name><surname>Levi</surname><given-names>M</given-names></name></person-group><year>2005</year><article-title>New antithrombotics in the treatment of thromboembolic disease</article-title><source>Eur J Intern Med</source><volume>16</volume><fpage>230</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">16084349</pub-id></citation></ref><ref id="pmed-0050043-b009"><citation citation-type="journal"><person-group><name><surname>Waxman</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>DE</given-names></name><name><surname>Arcuri</surname><given-names>KE</given-names></name><name><surname>Vlasuk</surname><given-names>GP</given-names></name></person-group><year>1990</year><article-title>Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa</article-title><source>Science</source><volume>248</volume><fpage>593</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">2333510</pub-id></citation></ref><ref id="pmed-0050043-b010"><citation citation-type="journal"><person-group><name><surname>Rezaie</surname><given-names>AR</given-names></name></person-group><year>2004</year><article-title>Kinetics of factor Xa inhibition by recombinant tick anticoagulant peptide: both active site and exosite interactions are required for a slow- and tight-binding inhibition mechanism</article-title><source>Biochemistry</source><volume>43</volume><fpage>3368</fpage><lpage>3375</lpage><pub-id pub-id-type="pmid">15035608</pub-id></citation></ref><ref id="pmed-0050043-b011"><citation citation-type="journal"><person-group><name><surname>Schaffer</surname><given-names>LW</given-names></name><name><surname>Davidson</surname><given-names>JT</given-names></name><name><surname>Vlasuk</surname><given-names>GP</given-names></name><name><surname>Siegl</surname><given-names>PK</given-names></name></person-group><year>1991</year><article-title>Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis</article-title><source>Circulation</source><volume>84</volume><fpage>1741</fpage><lpage>1748</lpage><pub-id pub-id-type="pmid">1833089</pub-id></citation></ref><ref id="pmed-0050043-b012"><citation citation-type="journal"><person-group><name><surname>Sitko</surname><given-names>GR</given-names></name><name><surname>Ramjit</surname><given-names>DR</given-names></name><name><surname>Stabilito</surname><given-names>II</given-names></name><name><surname>Lehman</surname><given-names>D</given-names></name><name><surname>Lynch</surname><given-names>JJ</given-names></name><etal/></person-group><year>1992</year><article-title>Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis</article-title><source>Circulation</source><volume>85</volume><fpage>805</fpage><lpage>815</lpage><pub-id pub-id-type="pmid">1735171</pub-id></citation></ref><ref id="pmed-0050043-b013"><citation citation-type="journal"><person-group><name><surname>Vlasuk</surname><given-names>GP</given-names></name><name><surname>Ramjit</surname><given-names>D</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Dunwiddie</surname><given-names>CT</given-names></name><name><surname>Nutt</surname><given-names>EM</given-names></name><etal/></person-group><year>1991</year><article-title>Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis</article-title><source>Thromb Haemost</source><volume>65</volume><fpage>257</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">2048051</pub-id></citation></ref><ref id="pmed-0050043-b014"><citation citation-type="journal"><person-group><name><surname>Stoll</surname><given-names>P</given-names></name><name><surname>Bassler</surname><given-names>N</given-names></name><name><surname>Hagemeyer</surname><given-names>CE</given-names></name><name><surname>Eisenhardt</surname><given-names>SU</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><etal/></person-group><year>2007</year><article-title>Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>27</volume><fpage>1206</fpage><lpage>1212</lpage><pub-id pub-id-type="pmid">17322097</pub-id></citation></ref><ref id="pmed-0050043-b015"><citation citation-type="journal"><person-group><name><surname>Joubert</surname><given-names>AM</given-names></name><name><surname>Louw</surname><given-names>AI</given-names></name><name><surname>Joubert</surname><given-names>F</given-names></name><name><surname>Neitz</surname><given-names>AW</given-names></name></person-group><year>1998</year><article-title>Cloning, nucleotide sequence and expression of the gene encoding factor Xa inhibitor from the salivary glands of the tick, Ornithodoros savignyi</article-title><source>Exp Appl Acarol</source><volume>22</volume><fpage>603</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">9890144</pub-id></citation></ref><ref id="pmed-0050043-b016"><citation citation-type="journal"><person-group><name><surname>Narasimhan</surname><given-names>S</given-names></name><name><surname>Montgomery</surname><given-names>RR</given-names></name><name><surname>Deponte</surname><given-names>K</given-names></name><name><surname>Tschudi</surname><given-names>C</given-names></name><name><surname>Marcantonio</surname><given-names>N</given-names></name><etal/></person-group><year>2004</year><article-title>Disruption of <named-content content-type="genus-species">Ixodes scapularis</named-content> anticoagulation by using RNA interference</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><fpage>1141</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">14745044</pub-id></citation></ref><ref id="pmed-0050043-b017"><citation citation-type="journal"><person-group><name><surname>Francischetti</surname><given-names>IM</given-names></name><name><surname>Mather</surname><given-names>TN</given-names></name><name><surname>Ribeiro</surname><given-names>JM</given-names></name></person-group><year>2004</year><article-title>Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, <named-content content-type="genus-species">Ixodes scapularis</named-content></article-title><source>Thromb Haemost</source><volume>91</volume><fpage>886</fpage><lpage>898</lpage><pub-id pub-id-type="pmid">15116248</pub-id></citation></ref><ref id="pmed-0050043-b018"><citation citation-type="journal"><person-group><name><surname>Francischetti</surname><given-names>IM</given-names></name><name><surname>Valenzuela</surname><given-names>JG</given-names></name><name><surname>Andersen</surname><given-names>JF</given-names></name><name><surname>Mather</surname><given-names>TN</given-names></name><name><surname>Ribeiro</surname><given-names>JM</given-names></name></person-group><year>2002</year><article-title>Ixolaris, a novel recombinant tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick, <named-content content-type="genus-species">Ixodes scapularis</named-content>: identification of factor X and factor Xa as scaffolds for the inhibition of factor VIIa/tissue factor complex</article-title><source>Blood</source><volume>99</volume><fpage>3602</fpage><lpage>3612</lpage><pub-id pub-id-type="pmid">11986214</pub-id></citation></ref><ref id="pmed-0050043-b019"><citation citation-type="journal"><person-group><name><surname>Nazareth</surname><given-names>RA</given-names></name><name><surname>Tomaz</surname><given-names>LS</given-names></name><name><surname>Ortiz-Costa</surname><given-names>S</given-names></name><name><surname>Atella</surname><given-names>GC</given-names></name><name><surname>Ribeiro</surname><given-names>JM</given-names></name><etal/></person-group><year>2006</year><article-title>Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade</article-title><source>Thromb Haemost</source><volume>96</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16807644</pub-id></citation></ref><ref id="pmed-0050043-b020"><citation citation-type="journal"><person-group><name><surname>Weitz</surname><given-names>JI</given-names></name><name><surname>Hudoba</surname><given-names>M</given-names></name><name><surname>Massel</surname><given-names>D</given-names></name><name><surname>Maraganore</surname><given-names>J</given-names></name><name><surname>Hirsh</surname><given-names>J</given-names></name></person-group><year>1990</year><article-title>Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors</article-title><source>J Clin Invest</source><volume>86</volume><fpage>385</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">2384594</pub-id></citation></ref><ref id="pmed-0050043-b021"><citation citation-type="journal"><person-group><name><surname>Ciprandi</surname><given-names>A</given-names></name><name><surname>de Oliveira</surname><given-names>SK</given-names></name><name><surname>Masuda</surname><given-names>A</given-names></name><name><surname>Horn</surname><given-names>F</given-names></name><name><surname>Termignoni</surname><given-names>C</given-names></name></person-group><year>2006</year><article-title><named-content content-type="genus-species">Boophilus microplus</named-content>: its saliva contains microphilin, a small thrombin inhibitor</article-title><source>Exp Parasitol</source><volume>114</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">16600217</pub-id></citation></ref><ref id="pmed-0050043-b022"><citation citation-type="journal"><person-group><name><surname>Iwanaga</surname><given-names>S</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Isawa</surname><given-names>H</given-names></name><name><surname>Morita</surname><given-names>A</given-names></name><name><surname>Yuda</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Identification and characterization of novel salivary thrombin inhibitors from the ixodidae tick, <named-content content-type="genus-species">Haemaphysalis longicornis</named-content></article-title><source>Eur J Biochem</source><volume>270</volume><fpage>1926</fpage><lpage>1934</lpage><pub-id pub-id-type="pmid">12709051</pub-id></citation></ref><ref id="pmed-0050043-b023"><citation citation-type="journal"><person-group><name><surname>Mans</surname><given-names>BJ</given-names></name><name><surname>Louw</surname><given-names>AI</given-names></name><name><surname>Neitz</surname><given-names>AW</given-names></name></person-group><year>2002</year><article-title>Amino acid sequence and structure modeling of savignin, a thrombin inhibitor from the tick, <named-content content-type="genus-species">Ornithodoros savignyi</named-content></article-title><source>Insect Biochem Mol Biol</source><volume>32</volume><fpage>821</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">12044499</pub-id></citation></ref><ref id="pmed-0050043-b024"><citation citation-type="journal"><person-group><name><surname>van de Locht</surname><given-names>A</given-names></name><name><surname>Stubbs</surname><given-names>MT</given-names></name><name><surname>Bode</surname><given-names>W</given-names></name><name><surname>Friedrich</surname><given-names>T</given-names></name><name><surname>Bollschweiler</surname><given-names>C</given-names></name><etal/></person-group><year>1996</year><article-title>The ornithodorin-thrombin crystal structure, a key to the TAP enigma</article-title><source>EMBO J</source><volume>15</volume><fpage>6011</fpage><lpage>6017</lpage><pub-id pub-id-type="pmid">8947023</pub-id></citation></ref><ref id="pmed-0050043-b025"><citation citation-type="journal"><person-group><name><surname>Koh</surname><given-names>CY</given-names></name><name><surname>Kazimirova</surname><given-names>M</given-names></name><name><surname>Trimnell</surname><given-names>A</given-names></name><name><surname>Takac</surname><given-names>P</given-names></name><name><surname>Labuda</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Variegin, a novel fast and tight binding thrombin inhibitor from the tropical bont tick</article-title><source>J Biol Chem</source><volume>282</volume><fpage>29101</fpage><lpage>29113</lpage><pub-id pub-id-type="pmid">17684009</pub-id></citation></ref><ref id="pmed-0050043-b026"><citation citation-type="journal"><person-group><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>Kleiman</surname><given-names>NS</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Feit</surname><given-names>F</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><etal/></person-group><year>2004</year><article-title>Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial</article-title><source>JAMA</source><volume>292</volume><fpage>696</fpage><lpage>703</lpage><pub-id pub-id-type="pmid">15304466</pub-id></citation></ref><ref id="pmed-0050043-b027"><citation citation-type="journal"><person-group><name><surname>Walport</surname><given-names>MJ</given-names></name></person-group><year>2001</year><article-title>Complement. Second of two parts</article-title><source>N Engl J Med</source><volume>344</volume><fpage>1140</fpage><lpage>1144</lpage><pub-id pub-id-type="pmid">11297706</pub-id></citation></ref><ref id="pmed-0050043-b028"><citation citation-type="journal"><person-group><name><surname>Walport</surname><given-names>MJ</given-names></name></person-group><year>2001</year><article-title>Complement. First of two parts</article-title><source>N Engl J Med</source><volume>344</volume><fpage>1058</fpage><lpage>1066</lpage><pub-id pub-id-type="pmid">11287977</pub-id></citation></ref><ref id="pmed-0050043-b029"><citation citation-type="journal"><person-group><name><surname>Mollnes</surname><given-names>TE</given-names></name><name><surname>Song</surname><given-names>WC</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group><year>2002</year><article-title>Complement in inflammatory tissue damage and disease</article-title><source>Trends Immunol</source><volume>23</volume><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">11929126</pub-id></citation></ref><ref id="pmed-0050043-b030"><citation citation-type="journal"><person-group><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Mahaffey</surname><given-names>KW</given-names></name><name><surname>Weaver</surname><given-names>WD</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><name><surname>Hochman</surname><given-names>JS</given-names></name><etal/></person-group><year>2003</year><article-title>Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial</article-title><source>Circulation</source><volume>108</volume><fpage>1184</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">12925454</pub-id></citation></ref><ref id="pmed-0050043-b031"><citation citation-type="journal"><person-group><name><surname>Mahaffey</surname><given-names>KW</given-names></name><name><surname>Van de</surname><given-names>WF</given-names></name><name><surname>Shernan</surname><given-names>SK</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Verrier</surname><given-names>ED</given-names></name><etal/></person-group><year>2006</year><article-title>Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview</article-title><source>Am Heart J</source><volume>152</volume><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">16875911</pub-id></citation></ref><ref id="pmed-0050043-b032"><citation citation-type="journal"><person-group><name><surname>Armstrong</surname><given-names>PW</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Adams</surname><given-names>PX</given-names></name><name><surname>Hamm</surname><given-names>C</given-names></name><name><surname>Holmes</surname><given-names>D</given-names><suffix>Jr</suffix></name><etal/></person-group><year>2007</year><article-title>Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial</article-title><source>JAMA</source><volume>297</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">17200474</pub-id></citation></ref><ref id="pmed-0050043-b033"><citation citation-type="journal"><person-group><name><surname>Hillmen</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>NS</given-names></name><name><surname>Schubert</surname><given-names>J</given-names></name><name><surname>Brodsky</surname><given-names>RA</given-names></name><name><surname>Socie</surname><given-names>G</given-names></name><etal/></person-group><year>2006</year><article-title>The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria</article-title><source>N Engl J Med</source><volume>355</volume><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">16990386</pub-id></citation></ref><ref id="pmed-0050043-b034"><citation citation-type="journal"><person-group><name><surname>Nunn</surname><given-names>MA</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Paesen</surname><given-names>GC</given-names></name><name><surname>Adamson</surname><given-names>S</given-names></name><name><surname>Lissina</surname><given-names>O</given-names></name><etal/></person-group><year>2005</year><article-title>Complement inhibitor of C5 activation from the soft tick <named-content content-type="genus-species">Ornithodoros moubata</named-content></article-title><source>J Immunol</source><volume>174</volume><fpage>2084</fpage><lpage>2091</lpage><pub-id pub-id-type="pmid">15699138</pub-id></citation></ref><ref id="pmed-0050043-b035"><citation citation-type="journal"><person-group><name><surname>Schroeder</surname><given-names>H</given-names></name><name><surname>Daix</surname><given-names>V</given-names></name><name><surname>Gillet</surname><given-names>L</given-names></name><name><surname>Renauld</surname><given-names>JC</given-names></name><name><surname>Vanderplasschen</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>The paralogous salivary anti-complement proteins IRAC I and IRAC II encoded by <named-content content-type="genus-species">Ixodes ricinus</named-content> ticks have broad and complementary inhibitory activities against the complement of different host species</article-title><source>Microbes Infect</source><volume>9</volume><fpage>247</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">17223370</pub-id></citation></ref><ref id="pmed-0050043-b036"><citation citation-type="journal"><person-group><name><surname>Tyson</surname><given-names>K</given-names></name><name><surname>Elkins</surname><given-names>C</given-names></name><name><surname>Patterson</surname><given-names>H</given-names></name><name><surname>Fikrig</surname><given-names>E</given-names></name><name><surname>de Silva</surname><given-names>A</given-names></name></person-group><year>2007</year><article-title>Biochemical and functional characterization of Salp20, an <named-content content-type="genus-species">Ixodes scapularis</named-content> tick salivary protein that inhibits the complement pathway</article-title><source>Insect Mol Biol</source><volume>16</volume><fpage>469</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">17651236</pub-id></citation></ref><ref id="pmed-0050043-b037"><citation citation-type="journal"><person-group><name><surname>Valenzuela</surname><given-names>JG</given-names></name><name><surname>Charlab</surname><given-names>R</given-names></name><name><surname>Mather</surname><given-names>TN</given-names></name><name><surname>Ribeiro</surname><given-names>JM</given-names></name></person-group><year>2000</year><article-title>Purification, cloning, and expression of a novel salivary anticomplement protein from the tick, <named-content content-type="genus-species">Ixodes scapularis</named-content></article-title><source>J Biol Chem</source><volume>275</volume><fpage>18717</fpage><lpage>18723</lpage><pub-id pub-id-type="pmid">10749868</pub-id></citation></ref><ref id="pmed-0050043-b038"><citation citation-type="journal"><person-group><name><surname>Ribeiro</surname><given-names>JM</given-names></name></person-group><year>1987</year><article-title><named-content content-type="genus-species">Ixodes dammini</named-content>: salivary anti-complement activity</article-title><source>Exp Parasitol</source><volume>64</volume><fpage>347</fpage><lpage>353</lpage><pub-id pub-id-type="pmid">3119364</pub-id></citation></ref><ref id="pmed-0050043-b039"><citation citation-type="journal"><person-group><name><surname>Roversi</surname><given-names>P</given-names></name><name><surname>Lissina</surname><given-names>O</given-names></name><name><surname>Johnson</surname><given-names>S</given-names></name><name><surname>Ahmat</surname><given-names>N</given-names></name><name><surname>Paesen</surname><given-names>GC</given-names></name><etal/></person-group><year>2007</year><article-title>The structure of OMCI, a novel lipocalin inhibitor of the complement system</article-title><source>J Mol Biol</source><volume>369</volume><fpage>784</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">17445829</pub-id></citation></ref><ref id="pmed-0050043-b040"><citation citation-type="journal"><person-group><name><surname>Hepburn</surname><given-names>NJ</given-names></name><name><surname>Williams</surname><given-names>AS</given-names></name><name><surname>Nunn</surname><given-names>MA</given-names></name><name><surname>Chamberlain-Banoub</surname><given-names>JC</given-names></name><name><surname>Hamer</surname><given-names>J</given-names></name><etal/></person-group><year>2007</year><article-title>In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick <named-content content-type="genus-species">Ornithodoros moubata</named-content></article-title><source>J Biol Chem</source><volume>282</volume><fpage>8292</fpage><lpage>8299</lpage><pub-id pub-id-type="pmid">17215252</pub-id></citation></ref><ref id="pmed-0050043-b041"><citation citation-type="journal"><person-group><name><surname>Hannier</surname><given-names>S</given-names></name><name><surname>Liversidge</surname><given-names>J</given-names></name><name><surname>Sternberg</surname><given-names>JM</given-names></name><name><surname>Bowman</surname><given-names>AS</given-names></name></person-group><year>2004</year><article-title>Characterization of the B-cell inhibitory protein factor in <named-content content-type="genus-species">Ixodes ricinus</named-content> tick saliva: a potential role in enhanced <named-content content-type="genus-species">Borrelia burgdoferi</named-content> transmission</article-title><source>Immunology</source><volume>113</volume><fpage>401</fpage><lpage>408</lpage><pub-id pub-id-type="pmid">15500628</pub-id></citation></ref><ref id="pmed-0050043-b042"><citation citation-type="journal"><person-group><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>A tick B-cell inhibitory protein from salivary glands of the hard tick, <named-content content-type="genus-species">Hyalomma asiaticum asiaticum</named-content></article-title><source>Biochem Biophys Res Commun</source><volume>343</volume><fpage>585</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">16554026</pub-id></citation></ref><ref id="pmed-0050043-b043"><citation citation-type="journal"><person-group><name><surname>Bugatti</surname><given-names>S</given-names></name><name><surname>Codullo</surname><given-names>V</given-names></name><name><surname>Caporali</surname><given-names>R</given-names></name><name><surname>Montecucco</surname><given-names>C</given-names></name></person-group><year>2007</year><article-title>B cells in rheumatoid arthritis</article-title><source>Autoimmun Rev</source><volume>6</volume><fpage>482</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">17643937</pub-id></citation></ref><ref id="pmed-0050043-b044"><citation citation-type="journal"><person-group><name><surname>Klawiter</surname><given-names>EC</given-names></name><name><surname>Cross</surname><given-names>AH</given-names></name></person-group><year>2007</year><article-title>B cells: no longer the nondominant arm of multiple sclerosis</article-title><source>Curr Neurol Neurosci Rep</source><volume>7</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">17488589</pub-id></citation></ref><ref id="pmed-0050043-b045"><citation citation-type="journal"><person-group><name><surname>Anguita</surname><given-names>J</given-names></name><name><surname>Ramamoorthi</surname><given-names>N</given-names></name><name><surname>Hovius</surname><given-names>JW</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>V</given-names></name><etal/></person-group><year>2002</year><article-title>Salp15, an <named-content content-type="genus-species">ixodes scapularis</named-content> salivary protein, inhibits CD4(&#x0002b;) T cell activation</article-title><source>Immunity</source><volume>16</volume><fpage>849</fpage><lpage>859</lpage><pub-id pub-id-type="pmid">12121666</pub-id></citation></ref><ref id="pmed-0050043-b046"><citation citation-type="journal"><person-group><name><surname>Garg</surname><given-names>R</given-names></name><name><surname>Juncadella</surname><given-names>IJ</given-names></name><name><surname>Ramamoorthi</surname><given-names>N</given-names></name><name><surname>Ashish</surname></name><name><surname>Ananthanarayanan</surname><given-names>SK</given-names></name><etal/></person-group><year>2006</year><article-title>Cutting edge: CD4 is the receptor for the tick saliva immunosuppressor, Salp15</article-title><source>J Immunol</source><volume>177</volume><fpage>6579</fpage><lpage>6583</lpage><pub-id pub-id-type="pmid">17082567</pub-id></citation></ref><ref id="pmed-0050043-b047"><citation citation-type="journal"><person-group><name><surname>Gillespie</surname><given-names>RD</given-names></name><name><surname>Dolan</surname><given-names>MC</given-names></name><name><surname>Piesman</surname><given-names>J</given-names></name><name><surname>Titus</surname><given-names>RG</given-names></name></person-group><year>2001</year><article-title>Identification of an IL-2 binding protein in the saliva of the Lyme disease vector tick, <named-content content-type="genus-species">Ixodes scapularis</named-content></article-title><source>J Immunol</source><volume>166</volume><fpage>4319</fpage><lpage>4326</lpage><pub-id pub-id-type="pmid">11254684</pub-id></citation></ref><ref id="pmed-0050043-b048"><citation citation-type="journal"><person-group><name><surname>Kotsyfakis</surname><given-names>M</given-names></name><name><surname>Sa-Nunes</surname><given-names>A</given-names></name><name><surname>Francischetti</surname><given-names>IM</given-names></name><name><surname>Mather</surname><given-names>TN</given-names></name><name><surname>Andersen</surname><given-names>JF</given-names></name><etal/></person-group><year>2006</year><article-title>Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick <named-content content-type="genus-species">Ixodes scapularis</named-content></article-title><source>J Biol Chem</source><volume>281</volume><fpage>26298</fpage><lpage>26307</lpage><pub-id pub-id-type="pmid">16772304</pub-id></citation></ref><ref id="pmed-0050043-b049"><citation citation-type="journal"><person-group><name><surname>Leboulle</surname><given-names>G</given-names></name><name><surname>Crippa</surname><given-names>M</given-names></name><name><surname>Decrem</surname><given-names>Y</given-names></name><name><surname>Mejri</surname><given-names>N</given-names></name><name><surname>Brossard</surname><given-names>M</given-names></name><etal/></person-group><year>2002</year><article-title>Characterization of a novel salivary immunosuppressive protein from <named-content content-type="genus-species">Ixodes ricinus</named-content> ticks</article-title><source>J Biol Chem</source><volume>277</volume><fpage>10083</fpage><lpage>10089</lpage><pub-id pub-id-type="pmid">11792703</pub-id></citation></ref><ref id="pmed-0050043-b050"><citation citation-type="journal"><person-group><name><surname>Paveglio</surname><given-names>SA</given-names></name><name><surname>Allard</surname><given-names>J</given-names></name><name><surname>Mayette</surname><given-names>J</given-names></name><name><surname>Whittaker</surname><given-names>LA</given-names></name><name><surname>Juncadella</surname><given-names>I</given-names></name><etal/></person-group><year>2007</year><article-title>The tick salivary protein, salp15, inhibits the development of experimental asthma</article-title><source>J Immunol</source><volume>178</volume><fpage>7064</fpage><lpage>7071</lpage><pub-id pub-id-type="pmid">17513755</pub-id></citation></ref><ref id="pmed-0050043-b051"><citation citation-type="journal"><person-group><name><surname>Hovius</surname><given-names>JWR</given-names></name><name><surname>de Jong</surname><given-names>MAWP</given-names></name><name><surname>den Dunnen</surname><given-names>J</given-names></name><name><surname>Litjens</surname><given-names>M</given-names></name><name><surname>Fikrig</surname><given-names>E</given-names></name><etal/></person-group><year>2008</year><article-title>Salp15 binding to DC-SIGN inhibits dendritic cell function by impairing nucleosome remodeling and decreasing mRNA stability of pro-inflammatory cytokines</article-title><source>PLoS Pathog</source><volume>4</volume><fpage>e31</fpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.ppat.0040031">10.1371/journal.ppat.0040031</ext-link></comment><pub-id pub-id-type="pmid">18282094</pub-id></citation></ref><ref id="pmed-0050043-b052"><citation citation-type="journal"><person-group><name><surname>Prevot</surname><given-names>PP</given-names></name><name><surname>Adam</surname><given-names>B</given-names></name><name><surname>Boudjeltia</surname><given-names>KZ</given-names></name><name><surname>Brossard</surname><given-names>M</given-names></name><name><surname>Lins</surname><given-names>L</given-names></name><etal/></person-group><year>2006</year><article-title>Anti-hemostatic effects of a serpin from the saliva of the tick <named-content content-type="genus-species">Ixodes ricinus</named-content></article-title><source>J Biol Chem</source><volume>281</volume><fpage>26361</fpage><lpage>26369</lpage><pub-id pub-id-type="pmid">16672226</pub-id></citation></ref><ref id="pmed-0050043-b053"><citation citation-type="journal"><person-group><name><surname>Burke</surname><given-names>G</given-names></name><name><surname>Wikel</surname><given-names>SK</given-names></name><name><surname>Spielman</surname><given-names>A</given-names></name><name><surname>Telford</surname><given-names>SR</given-names></name><name><surname>McKay</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Hypersensitivity to ticks and Lyme disease risk</article-title><source>Emerg Infect Dis</source><volume>11</volume><fpage>36</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15705320</pub-id></citation></ref><ref id="pmed-0050043-b054"><citation citation-type="journal"><person-group><name><surname>de la Fuente</surname><given-names>J</given-names></name><name><surname>Kocan</surname><given-names>KM</given-names></name></person-group><year>2006</year><article-title>Strategies for development of vaccines for control of ixodid tick species</article-title><source>Parasite Immunol</source><volume>28</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">16842264</pub-id></citation></ref><ref id="pmed-0050043-b055"><citation citation-type="journal"><person-group><name><surname>Labuda</surname><given-names>M</given-names></name><name><surname>Trimnell</surname><given-names>AR</given-names></name><name><surname>Li&#x0010d;kov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Kazim&#x000ed;rov&#x000e1;</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>GM</given-names></name><etal/></person-group><year>2006</year><article-title>An antivector vaccine protects against a lethal vector-borne pathogen</article-title><source>PLoS Pathog</source><volume>2</volume><fpage>e27</fpage><comment>doi:<ext-link ext-link-type="doi" xlink:href="10.1371/journal.ppat.0020027">10.1371/journal.ppat.0020027</ext-link></comment><pub-id pub-id-type="pmid">16604154</pub-id></citation></ref><ref id="pmed-0050043-b056"><citation citation-type="journal"><person-group><name><surname>Trimnell</surname><given-names>AR</given-names></name><name><surname>Davies</surname><given-names>GM</given-names></name><name><surname>Lissina</surname><given-names>O</given-names></name><name><surname>Hails</surname><given-names>RS</given-names></name><name><surname>Nuttall</surname><given-names>PA</given-names></name></person-group><year>2005</year><article-title>A cross-reactive tick cement antigen is a candidate broad-spectrum tick vaccine</article-title><source>Vaccine</source><volume>23</volume><fpage>4329</fpage><lpage>4341</lpage><pub-id pub-id-type="pmid">15913855</pub-id></citation></ref><ref id="pmed-0050043-b057"><citation citation-type="journal"><person-group><name><surname>Kunze</surname><given-names>U</given-names></name><name><surname>Baumhackl</surname><given-names>U</given-names></name><name><surname>Bretschneider</surname><given-names>R</given-names></name><name><surname>Chmelik</surname><given-names>V</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B</given-names></name><etal/></person-group><year>2005</year><article-title>The Golden Agers and Tick-borne encephalitis. Conference report and position paper of the International Scientific Working Group on Tick-borne encephalitis</article-title><source>Wien Med Wochenschr</source><volume>155</volume><fpage>289</fpage><lpage>294</lpage><pub-id pub-id-type="pmid">16035390</pub-id></citation></ref><ref id="pmed-0050043-b058"><citation citation-type="journal"><person-group><name><surname>Prevot</surname><given-names>PP</given-names></name><name><surname>Couvreur</surname><given-names>B</given-names></name><name><surname>Denis</surname><given-names>V</given-names></name><name><surname>Brossard</surname><given-names>M</given-names></name><name><surname>Vanhamme</surname><given-names>L</given-names></name><etal/></person-group><year>2007</year><article-title>Protective immunity against <named-content content-type="genus-species">Ixodes ricinus</named-content> induced by a salivary serpin</article-title><source>Vaccine</source><volume>25</volume><fpage>3284</fpage><lpage>3292</lpage><pub-id pub-id-type="pmid">17270322</pub-id></citation></ref></ref-list><fn-group><fn id="n3" fn-type="current-aff"><p>Joppe W. R. Hovius is with the Center for Experimental and Molecular Medicine, the Department of Internal Medicine, and the Center for Infection and Immunity Amsterdam at the University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands, as well as the Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America. Marcel Levi is with the Department of Internal Medicine at the University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands. Erol Fikrig is with the Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America.</p></fn><fn id="n1" fn-type="financial-disclosure"><p><bold>Funding:</bold> JWRH is supported by the Netherlands Organisation for Health Research and Development, and EF is the recipient of a Burroughs Wellcome Clinical Scientist Award in Translational Research. The authors received no specific funding for this article.</p></fn><fn id="n2" fn-type="conflict"><p><bold>Competing Interests:</bold> The authors have declared that no competing interests exist.</p></fn></fn-group></back></article>





